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Abstract
Objective: Hyperuricemia is associated with an increased risk of metabolic and cardiovascular diseases. There are
pronounced sex differences in the levels of uric acid. It is largely unknown whether or not reproductive parameters which
induce hormonal changes are responsible for this. We examined if there are associations between reproductive parameters
and uric acid levels in a female population-based sample.
Methods: In this cross-sectional analysis, data of 1530 women aged 32 to 81 years participating in the KORA F4 study,
conducted between 2006 and 2008 in Southern Germany were used. Reproductive parameters were obtained by
standardized interviews. Uric acid levels were tested by the uricase method. The whole study sample and stratified in pre-
and postmenopausal women was analyzed.
Results: Menopausal status and earlier age at menarche were associated with higher serum uric acid levels (age-adjusted: p-
values 0.003, ,0.001 respectively; after multivariable adjustment, including BMI: p-values 0.002, 0.036). A history of oral
contraceptive use showed an association with uric acid levels only after multivariable adjustment (p-value 0.009). Hot
flushes showed an association with uric acid levels only after age-adjustment (p-value 0.038), but lost significance after
adding other confounders. Other reproductive factors, including parity, current or ever use of hormone replacement
therapy, current use of oral contraceptives, hysterectomy, bilateral oophorectomy, or depressive mood related to
menopausal transition were not associated with uric acid levels.
Conclusions: Postmenopausal status, earlier age at menarche and a history of oral contraceptive use were independently
associated with higher serum uric acid concentrations in women from the general population. Further studies, especially
longitudinal population-based studies investigating the relationship of female reproductive parameters with uric acid levels
are necessary to confirm our findings.
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Introduction
Hyperuricemia is not only the main risk factor for gout in
women [1,2], but also associated with chronic diseases, such as the
metabolic syndrome [3,4], type 2 diabetes [5] and cardiovascular
diseases [6,7] in women as well as in men with some sex-related
dissimilarities [8]. There are pronounced sex-specific aspects in the
levels of uric acid [2,9]. In women compared to men uric acid
levels are lower in younger ages, but the difference becomes
smaller with older ages, and especially after menopause this gender
difference is lost [10,11]. The main factor for this is presumed to
be a female hormone influence. But the underlying pathways and
their importance have been sparsely examined. During pregnancy,
uric acid levels initially decrease compared to pre-pregnancy
values and in the second half of the pregnancy they increase and
are higher than before pregnancy [12], pointing towards hormonal
influences on uric acid levels. Genetic factors are known to
influence uric acid levels, with a stronger effect in women than in
men [9]. Some reproductive events which occur over the life span
of women are influenced by genetic traits as well, like age at
menarche [13].
Some studies have examined selected reproductive factors and
its influence on gout prevalence. Earlier menopause [14,15] was
shown to be a risk factor for gout while hormone replacement
therapy seems to modestly reduce the risk of gout [15]. Other
research has examined the menopausal status or menopausal
transition and its effect on uric acid levels [10,11,16]. It could be
shown that serum uric acid levels rise after menopause. Whether
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this is simply an age effect, or if the hormonal changes during the
menopause have a direct effect on uric acid levels needs further
exploration. Postmenopausal hormone replacement therapy
reduces uric acid levels [10,17,18]. Thus, prior studies have
investigated the effect of selected reproductive parameters on uric
acid levels to some extend, with a certain lack of population-based
studies. In addition, to the best of our knowledge, the role of some
reproductive factors such as age at menarche have not been
previously studied.
Thus, the aim of this study was to investigate whether there is an
association between a variety of reproductive parameters and uric
acid levels in women from the general population.
Methods
Subjects
The KORA F4 study (2006–2008) contains 7-year follow-up
data of the KORA S4 study (1999–2001), a population-based
health survey conducted in the city of Augsburg and the two
surrounding counties. For the S4 baseline study, a total sample of
6640 subjects was drawn from the target population consisting of
all German residents of the region aged 25 to 74 years. The study
design, sampling method and data collection have been described
in detail elsewhere [8,19].
Of the 4261 participants in S4, 3080 took part in the F4 follow-
up study. Participants were not included in F4 if they had died in
the time in-between (n = 176, 4%), relocated outside the study
region, were lost to follow-up (n = 206, 5%) or had demanded
deletion of their contact data (n = 12, 0.2%). Of the remaining
3867 eligible persons, 174 could not be contacted, 218 were
unable to participate in the F4 study because they were too ill or
had no time, and 395 did not want to take part in the follow-up.
The resulting response was 79.6%. The current study was
restricted to 1594 female subjects, aged 32 to 81 years at follow-up.
We excluded all women for whom no or incomplete
information on uric acid levels (n = 8) or any of the covariables
was available (n = 56). The final analysis thus included 1530
women.
Ethics Statement
The investigations were carried out in accordance with the
Declaration of Helsinki, including written informed consent of all
study participants. The study was approved by the Ethics
Committee of the Bavarian Medical Association.
Data collection
Information on socio-demographic variables, physical activity
level, medication use, alcohol consumption, smoking habits and
reproductive history was obtained by trained medical staff during
a standardized face-to-face interview. All study participants were
asked to bring original packaging of their medications used during
the last 7 days before the study examination. Pharmaceutical
control numbers, names etc. were recorded and ATC (Anatomical
Therapeutic Chemical Classification System) codes assigned
accordingly, including uricosuric and uricostatic medication. In
addition, all study participants underwent a standardized medical
examination. All measurement procedures have been described in
detail elsewhere [8]. Anthropometric measurements were taken
after the participants had removed their shoes, heavy clothing and
belts. Body height was measured to the nearest 0.1 cm and weight
to the nearest 0.1 kg. BMI was calculated as weight [kg] divided by
height2 [m2]. Waist circumference (WC) was measured at the level
midway between the lower rib margin and the iliac crest. Actual
hypertension was defined as blood pressure values greater than
140/90 mmHg or the use of antihypertensive medication, given
that the participants were aware of being hypertensive. Partici-
pants were classified as active during leisure time if they regularly
participated in sports in the summer and winter and if they were
active for .1 h/wk in either season. Women who consumed on
average more than 20 g alcohol per day were regarded as heavy
alcohol drinkers.
Clinical chemical measurements
A venous blood sample was obtained from all study participants
while sitting. Serum levels of uric acid were analysed by the uricase
method (enzymatic color-test, URCA Flex), total cholesterol and
high-density lipoprotein cholesterol (HDL-C) with a CHOD-PAP
method (CHOL Flex) and serum creatinine with the analyzer
Dimension RxL, all assays from Dade Behring, Germany.
Assessment of reproductive parameters
Reproductive parameters were obtained by a personal interview
by trained medical staff in the KORA S4 and F4 survey.
Age at menarche was defined as age at the first menstrual
bleeding, assessed in full years. The question, which was asked in
S4 was open-ended: ‘‘At what age did you have your first
menstrual period (menarche)?’’ [20]. Women were asked in S4
and F4 to recall their age at their last menstruation, number of
pregnancies, live-born children, if they ever used oral contracep-
tives or hormone replacement therapy. Women were defined
postmenopausal at the absence of menses for 12 consecutive
months. If the underlying reason for the absence of menses was a
pregnancy or a lactation period, women were classified as
premenopausal. Women were regarded as postmenopausal if they
had bilateral oophorectomy (either alone or in combination with
hysterectomy) and had hysterectomy without bilateral oophorec-
tomy and were above 50 years in case there was no onset of
menopause before hysterectomy. Women currently under hor-
mone replacement therapy were stratified to the group of
postmenopausal women in the analysis. Parity was defined as
the number of deliveries, categorized in three groups: Nulliparae,
1–2 deliveries and three deliveries or more. On the basis of the
classified medication data the categories ‘‘current use of oral
contraceptives’’ and ‘‘current use of hormone replacement
therapy’’ were created. Ever use of oral contraception or hormone
replacement therapy was assessed in the interviews. Furthermore
the women were asked about the presence of two symptoms of the
menopausal transition: Hot flashes and depressive mood. Due to
missing values and the difficulty to assign women an exact date of
menopause, e.g. due to ongoing vaginal bleeding because of
hormone replacement therapy or hysterectomy while still being
premenopausal, this variable is only available for 693 women out
of the 959 women classified as postmenopausal. The variable time
since menopause was created by calculating the difference
between age at menopause and current age.
Statistical analyses
Basic characteristics of the study population were analyzed for
the whole sample and stratified by quartiles of serum uric acid
levels. The cut-offs are below 3.70 mg/dl for quartile 1 (Q1), 3.70
to 4.34 mg/dl (Q2), 4.34 to 5.15 mg/dl (Q3) and above 5.15 mg/
dl (Q4). For normally distributed variables the mean and standard
deviation and for non-normally distributed variables, the median
and the interquartile range were given. For categorical variables
percentages were calculated. For testing differences between uric
acid categories, chi-square-tests for categorized outcome variables
and regression models for linear outcomes were performed.
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Means of uric acid levels are presented for grouped reproductive
variables. Covariance-adjusted means were calculated. In the
analyses three models were fitted, one controlling for age [years],
the second model controlled for age [years] and BMI [kg/m2] and
the third model controlled for the following variables: age [years],
BMI [kg/m2], alcohol intake .20 g/day (yes/no), current use of
uricosuric or uricostatic medication (yes/no) and serum creatinine
[mg/dl]. The confounder were on one hand chosen due to
literature research, which shows that age [10], BMI [11,16] and
alcohol consumption [16] is highly associated with serum uric acid
levels. We included current use of uricosuric or uricostatic
medication and serum creatinine, because of their direct influence
on serum uric acid levels, furthermore we added current
hypertension (yes/no), HDL cholesterol [mg/dl], total cholesterol
[mg/dl], history of diabetes (yes/no) and education [years]. The
analyses were performed for the whole sample and additionally
stratified in the two groups of premenopausal and postmenopausal
women. Included in the group of postmenopausal women were
women currently under hormone therapy. General linear models
were fitted using SAS procedure GLM.
Significance tests were two-tailed and p-values less than 0.05
were considered statistically significant. All analyses were per-
formed using SAS (version 9.2, SAS Institute Inc, Cary, NC,
USA).
Results
Of the 1530 women included in the final analysis, 571 were
classified premenopausal and 959 were classified postmenopausal.
The mean age of all study participants was 55.7 years (standard
deviation 13.1). The mean age of premenopausal women was 42.4
(5.8) years and of postmenopausal women 63.6 (9.2) years.
Characteristics of the study sample according to quartiles of
serum uric acid levels are shown in Table 1. In summary, women
with higher uric acid levels in comparison to the participants with
lower uric acid levels were more likely to be older, have a higher
BMI and waist circumference, a higher systolic and diastolic blood
pressure, were more likely to suffer from hypertension, had higher
mean serum creatinine levels, and lower HDL cholesterol levels.
They were less physically active, were more likely to use uricosuric
or uricostatic medication, were more likely to suffer from diabetes
and reported less years of education. Women with higher uric acid
levels had a lower age at menarche, reported more often a history
of hysterectomy and more often the symptom of hot flashes during
menopausal transition.
Table 2 shows the association between reproductive parameters
and mean uric acid levels for the total sample. After age-
adjustment, menopausal status, lower age at menarche and the
presence of hot flashes were significantly associated with higher
mean uric acid levels. After full adjustment, including BMI, the
association with hot flashes lost significance, but the association
with age at menarche and menopause status remained significant.
Ever use of oral contraceptives showed an association with uric
acid levels after adjustment for BMI and multiple confounders, but
not in the age-adjusted analysis.
Table 3 and Table 4 show the results for the stratified analyses.
In premenopausal women (Table 3) earlier age at menarche was
associated with higher uric acid levels after adjustment for age and
additional adjustment for BMI. This association lost significance
after multivariable adjustment. In postmenopausal women
(Table 4), age at menarche and ever use of hormone replacement
therapy were associated with higher uric acid levels after
adjustment for age, but these associations did not remain
significant after further adjustment. Ever use of oral contraceptives
showed no association with uric acid levels after adjustment for
age, but after further adjustment for BMI and multivariable
adjustment, the association became significant.
Discussion
This study demonstrates that age at menarche and menopausal
status are inversely associated with mean serum uric acid levels,
even after adjustment for a variety of confounding variables. The
association with age at menarche was stronger in premenopausal
than in postmenopausal women, although significance was lost
after multivariable-adjustment probably due to a lack of power in
these stratified analyses. Ever use of oral contraceptives showed an
association with uric acid levels after adjustment for BMI and
multiple confounders. In stratified analyses, this relationship could
be shown in postmenopausal women only.
Reproductive events which occur over the life-span of women
are expected to influence hormonal levels, especially estrogen
levels. Estrogens have an impact on the renal tubular handling of
uric acid [18,21,22] and therefore are possibly explaining the
underlying relation between some reproductive parameters and
uric acid levels, suggesting that premenopausal levels of estrogen in
women cause a greater renal clearance of uric acid [18,21,22], but
the underlying mechanisms are not fully known [22]. Adminis-
tration of estrogen to males decreases serum uric acid levels [22],
which could be shown as well in transsexual persons under long-
term treatment with sex steroids undergoing cross-sex hormone
therapy [23]. Whether or not testosterone is of influence is not
fully understood [23]. Therefore, one possible explanation for the
gender difference could be the different estrogen levels in men and
women, but this topic needs further research.
So far, the mechanisms underlying the association of age at
menarche and uric acid levels are unclear. It is possible that early
age at menarche only presents a marker for childhood obesity,
which is known to induce earlier menarche. A recently published
study shows that age at menarche is associated with diabetes,
attenuated by adult and adolescent BMI, but less with BMI
measured earlier in childhood [24]. Whether it acts in combina-
tion or as a risk factor by itself or through sex hormone changes
over the life span needs further research. Existing data suggest that
about half of the variance in the timing of puberty is due to genetic
reasons [25], and there seems to be a genetic basis for the
phenotypic associations between age at menarche and BMI [13].
Prospective studies are needed to understand the underlying
mechanisms by which lower age at menarche increases uric acid
levels in adulthood and whether there is a causal link to the
development of chronic diseases.
Parity was not associated with uric acid levels in our study. Since
parity was shown to be associated with cardiovascular disease [26]
and the metabolic syndrome [27,28], a different underlying
causality could be assumed. Further studies confirming our results
are needed.
Current use of oral contraceptives didn’t show an association
with uric acid levels, but ever use of oral contraceptives was
independently associated with higher levels of uric acid. In
stratified analyses this relationship was found in postmenopausal
but not in premenopausal women.
Menopausal status was associated with uric acid levels after
adjustment for age and multivariable-adjustment. This is in good
agreement with other studies, which showed that the postmeno-
pause is associated with higher uric acid levels [10,11],
independently of age. In a much larger study than the present
one, Hak et al. examined 7662 women above age 20 and showed
an independent association of menopause with higher serum uric
Reproductive Factors and Uric Acid Levels
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acid levels. Postmenopausal hormone use was associated with
lower uric acid levels [10]. The lack of association between
hormone replacement therapy and uric acid levels in our study
may be due to lack of power and might be due to the difference of
the study sample: The mean age of premenopausal women in
Hak’s study was 34 years, which is much younger than the
premenopausal women in our study. Another explanation might
be a difference in the usage of the hormone replacement therapy.
Hak’s study was conducted between 1988 and 1994 in an US
population [10], while our study sample was examined in 2006 to
2008 in South Germany, suggesting a different drug range, dosage
and difference in administration. This possibly influences the
results. Further research is needed to assess this in depth.
The lack of association between hysterectomy and uric acid
levels in the present study is not surprising, since a hysterectomy
does not cause a change in the hormone system. Contrary,
bilateral oophorectomy leads to a surgical menopause and thus a
change in the hormone system and therefore could possibly have
an influence on uric acid levels, as it has been shown by Hak et al.
[10]. In our study only 62 women had a bilateral oophorectomy,
Table 1. Characteristics of the study population, mean (SD) and prevalences (%) of variables according to quartiles of uric acid,
KORA F4 study (women 32–81 years).
Uric Acid (mg/dl)
All probands Q1: Q2: Q3: Q4: p-value
,3.70 3.70 to ,4.34 4.34 to ,5.15 $5.15
n 1530 382 382 383 383
Age (years) 55.7 (13.1) 50.3 (12.1) 53.2 (12.5) 57.0 (12.8) 62.2 (11.8) ,0.0001
BMI (kg/m2) 27.3 (5.3) 24.4 (4.0) 26.2 (4.6) 28.0 (4.9) 30.7 (5.5) ,0.0001
Waist circumference (cm) 88.1 (13.3) 80.3 (10.5) 85.1 (11.2) 90.0 (12.7) 97.1 (12.5) ,0.0001
Systolic blood pressure (mmHg) 117.2 (18.1) 112.5 (15.7) 115.0 (17.4) 117.9 (18.5) 123.2 (18.7) ,0.0001
Diastolic blood pressure (mmHg) 72.9 (9.4) 71.6 (9.2) 72.6 (8.6) 73.4 (9.3) 74.2 (10.3) 0.013
Actual hypertension (%)a 28.1 10.5 17.5 30.3 54.0 ,0.0001
Serum creatinine (mg/dl)b 0.80 (0.71–0.89) 0.75 (0.66–0.82) 0.78 (0.70–0.85) 0.80 (0.72–0.89) 0.87 (0.77–0.95) ,0.0001
HDL cholesterol (mg/dl) 61.2 (14.3) 64.9 (14.0) 63.8 (13.9) 60.5 (14.4) 55.7 (12.9) ,0.0001
Total cholesterol (mg/dl) 218.4 (39.5) 208.9 (35.2) 217.2 (38.6) 220.3 (40.7) 227.1 (41.2) ,0.0001
Current use of uricosuric or uricostatic
medication (%)
1.4 0.3 0.8 0.8 3.9 ,0.0001
Current smoking (%) 15.4 16.8 17.2 17.0 10.4 0.542
Alcohol intake (.20 g/day in %) 14.8 16.0 16.2 13.1 13.8 0.816
Physically active (%) 55.6 61.4 56.9 53.5 50.7 0.154
History of diabetes (%) 5.9 2.4 2.3 5.2 13.8 ,0.0001
Education $12 years (%) 27.8 36.2 31.6 25.6 17.8 ,0.0001
Age at menarche (years) 13.5 (1.6) 13.6 (1.5) 13.5 (1.6) 13.4 (1.6) 13.5 (1.6) 0.338
Nulliparae (%) 14.8 16.5 15.1 16.4 11.0 0.989
Multiparae ($3 deliveries, %) 36.4 32.0 36.3 36.0 41.3 0.104
Postmenopausal status (%)c 50.6 33.1 43.1 56.7 69.5 0.004
Age at menopause (years)d 48.9 (5.1) 48.5 (5.5) 49.0 (5.3) 48.6 (5.1) 49.2 (4.7) 0.297
Time since menopause (years)d 15.8 (9.2) 13.9 (8.9) 14.8 (9.2) 15.4 (9.5) 17.7 (8.8) 0.001
Current use of HRT (%) 9.0 6.3 11.0 8.4 10.2 0.698
Ever use of HRT (%) 41.7 35.4 39.7 44.1 47.5 0.454
Current use of OC (%) 6.5 10.2 6.8 7.0 1.8 0.706
Ever use of OC (%) 73.7 82.4 76.2 72.3 64.0 0.103
Hysterectomy (%) 22.3 15.2 18.8 21.9 33.2 0.036
Bilateral oophorectomy (%) 4.1 1.6 3.1 5.0 6.5 0.118
Hot flashes (%) 35.6 28.6 37.9 36.3 39.7 0.029
Depressive mood (%) 33.8 32.0 33.9 31.9 37.3 0.628
Abbreviations: Q: quartile, BMI: body mass index, SD: standard deviation, OC: oral contraceptives, HRT: hormone replacement therapy, HDL: high density lipoprotein.
Data are expressed as mean (SD) or percentages respectively.
p-value: chi-square test was performed to test the difference between the parameters and continuous uric acid levels.
adefined as use of antihypertensive medication, being aware of having hypertension or blood pressure values greater than 140/90 mmHg.
bdue to the skewed distribution of creatinine, the median and interquartile range is shown.
cdefined as postmenopausal women and women under hormone replacement therapy.
dn = 693, due to missing values of age at menopause.
doi:10.1371/journal.pone.0032668.t001
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Table 2. Mean uric acid levels stratified by reproductive parameters, the KORA F4 study (N = 1530).
lsmean CI lsmean CI lsmean CI p-value*
Age at menarche ,12 years 12–15 years .15 years
n = 119 n = 1250 n = 161
Model 1 4.70 4,50 4.90 4.52 4.46 4.58 4.27 4.09 4.44 ,0.001
Model 2 4.60 4.41 4.78 4.52 4.46 4.57 4.35 4.19 4.51 0.033
Model 3 4.58 4.41 4.75 4.52 4.46 4.57 4.36 4.21 4.51 0.036
Parity Nulliparae 1–2 deliveries .2 deliveries
n = 226 n = 747 n = 557
Model 1 4.44 4.30 4.59 4.50 4.42 4.58 4.53 4.44 4.63 0.188
Model 2 4.51 4.38 4.65 4.51 4.44 4.58 4.49 4.41 4.58 0.946
Model 3 4.52 4.39 4.64 4.50 4.43 4.57 4.51 4.43 4.59 0.872
Postmenopausal status Yes No
n = 959 n = 571
Model 1 4.61 4.52 4.70 4.33 4.20 4.46 0.003
Model 2 4.59 4.51 4.67 4.36 4.25 4.48 0.011
Model 3 4.60 4.52 4.68 4.34 4.23 4.46 0.002
Current use of HRT Yes No
n = 137 n = 1393
Model 1 4.47 4.29 4.66 4.51 4.45 4.57 0.729
Model 2 4.55 4.37 4.72 4.50 4.45 4.55 0.626
Model 3 4.58 4.42 4.75 4.50 4.45 4.55 0.318
Ever use of HRT Yes No
n = 638 n = 892
Model 1 4.45 4.36 4.54 4.54 4.47 4.62 0.122
Model 2 4.49 4.41 4.57 4.51 4.45 4.58 0.661
Model 3 4.51 4.43 4.59 4.50 4.43 4.56 0.815
Current use of OC Yes No
n = 99 n = 1431
Model 1 4.41 4.19 4.64 4.51 4.45 4.57 0.419
Model 2 4.46 4.25 4.67 4.51 4.45 4.56 0.674
Model 3 4.40 4.20 4.60 4.51 4.46 4.56 0.293
Ever use of OC Yes No
n = 1128 n = 402
Model 1 4.52 4.46 4.59 4.45 4.33 4.58 0.360
Model 2 4.54 4.48 4.61 4.40 4.28 4.51 0.033
Model 3 4.55 4.49 4.61 4.38 4.27 4.48 0.009
Hysterectomy Yes No
n = 341 n = 1189
Model 1 4.61 4.49 4.73 4.47 4.41 4.54 0.060
Model 2 4.55 4.43 4.66 4.49 4.43 4.55 0.428
Model 3 4.55 4.45 4.66 4.49 4.44 4.55 0.154
Bilateral oophorectomy Yes No
n = 62 n = 1468
Model 1 4.68 4.40 4.95 4.50 4.44 4.55 0.223
Model 2 4.60 4.35 4.86 4.50 4.45 4.55 0.443
Model 3 4.65 4.41 4.89 4.50 4.45 4.55 0.230
Hot flashes Yes No
n = 545 n = 985
Model 1 4.58 4.49 4.68 4.46 4.39 4.53 0.038
Model 2 4.53 4.45 4.62 4.49 4.43 4.55 0.424
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and some of them were already postmenopausal at the time of
surgery, possibly explaining the lack of association.
Hot flashes and menopausal induced depressive mood were not
associated with uric acid levels in our study. Only in the age-
adjusted model of the whole population there seemed to be a slight
association between hot flashes and uric acid levels, which needs to
be assessed in further studies. After adjustment for BMI, this
association was lost. Obesity has been described to be associated
with fewer hot flashes [29]. One theory to explain this is that it is
due to relatively elevated estrogen levels through the aromatization
of estrogen in body fat. BMI is highly associated with uric acid
levels [11,16]. So if there is an effect, our data suggest that it is
probably only a small one and other regulations are more
dominant. The underlying physiology and risk factors for hot
flashes have not been examined extensively and most is not
known. So far, there is a lack of other studies investigating the
lsmean CI lsmean CI lsmean CI p-value*
Model 3 4.56 4.48 4.64 4.48 4.42 4.54 0.126
Depressive mood Yes No
n = 517 n = 1013
Model 1 4.50 4.40 4.60 4.51 4.44 4.58 0.904
Model 2 4.50 4.41 4.59 4.51 4.45 4.57 0.839
Model 3 4.51 4.43 4.59 4.50 4.44 4.56 0.907
Abbreviations: CI: Confidence Interval, BMI: Body mass index, lsmean: least square mean.
*the p-values (linear model) are reported for age at menarche and parity as continuous variable.
Model 1: adjusted for age (in years).
Model 2: adjusted for age (in years) and BMI (kg/m2).
Model 3: adjusted for age (in years), BMI (kg/m2), serum creatinine (mg/dl), current use of uricosuric or uricostatic medication (yes/no), alcohol consumption (.20 g/d in
%), current hypertension (yes/no), HDL cholesterol (mg/dl), total cholesterol (mg/dl), history of diabetes (yes/no) and education (years).
doi:10.1371/journal.pone.0032668.t002
Table 2. Cont.
Table 3. Mean uric acid levels stratified by reproductive parameters in premenopausal women, the KORA F4 study (total n = 571).
lsmean CI lsmean CI lsmean CI p-value*
Age at menarche ,12 years 12–15 years .15 years
n = 48 n = 488 n = 35
Model 1 4.29 4.05 4.54 4.03 3.95 4.10 3.93 3.64 4.22 0.002
Model 2 4.15 3.93 4.38 4.03 3.96 4.10 4.01 3.74 4.27 0.048
Model 3 4.12 3.90 4.34 4.04 3.97 4.11 4.01 3.75 4.27 0.083
Parity Nulliparae 1–2 deliveries .2 deliveries
n = 110 n = 283 n = 178
Model 1 4.04 3.88 4.21 4.04 3.94 4.14 4.04 3.91 4.17 0.814
Model 2 4.05 3.89 4.20 4.04 3.95 4.14 4.04 3.92 4.16 0.971
Model 3 4.05 3.90 4.20 4.04 3.94 4.13 4.05 3.93 4.16 0.977
Current use of OC Yes No
n = 99 n = 472
Model 1 4.00 3.83 4.18 4.05 3.97 4.13 0.616
Model 2 4.03 3.87 4.19 4.05 3.97 4.12 0.834
Model 3 4.00 3.84 4.16 4.05 3.98 4.12 0.607
Ever use of OC Yes No
n = 533 n = 38
Model 1 4.04 3.97 4.12 4.04 3.76 4.32 0.989
Model 2 4.05 3.98 4.11 3.99 3.74 4.25 0.688
Model 3 4.04 3.98 4.11 4.03 3.78 4.28 0.931
Abbreviations: CI: Confidence Interval, BMI: Body mass index, lsmean: least square means.
*the p-values (linear model) are reported for age at menarche and parity as continuous variable.
Model 1: adjusted for age (in years).
Model 2: adjusted for age (in years) and BMI (kg/m2).
Model 3: adjusted for age (in years), BMI (kg/m2), serum creatinine (mg/dl), current use of uricosuric or uricostatic medication (yes/no), alcohol consumption (.20 g/d in
%), current hypertension (yes/no), HDL cholesterol (mg/dl), total cholesterol (mg/dl), history of diabetes (yes/no) and education (years).
doi:10.1371/journal.pone.0032668.t003
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Table 4. Reproductive parameters and uric acid levels in postmenopausal women, including women currently under hormone
replacement therapy, the KORA F4 study (n = 959).
lsmean CI lsmean CI lsmean CI p-value*
Age at menarche ,12 years 12–15 years .15 years
n = 71 n = 762 n = 126
Model 1 4.92 4.64 5.20 4.81 4.73 4.90 4.50 4.29 4.72 0.017
Model 2 4.86 4.60 5.12 4.80 4.72 4.88 4.59 4.39 4.79 0.178
Model 3 4.82 4.57 5.07 4.80 4.73 4.88 4.61 4.43 4.80 0.254
Parity Nulliparae 1–2 deliveries .2 deliveries
n = 116 n = 464 n = 379
Model 1 4.64 4.42 4.86 4.77 4.66 4.88 4.83 4.71 4.96 0.142
Model 2 4.79 4.58 4.99 4.78 4.68 4.89 4.78 4.66 4.89 0.975
Model 3 4.80 4.61 5.00 4.77 4.68 4.87 4.78 4.68 4.89 0.801
Current use of HRT Yes No
n = 137 n = 822
Model 1 4.69 4.48 4.90 4.80 4.71 4.88 0.355
Model 2 4.78 4.59 4.97 4.78 4.70 4.86 0.979
Model 3 4.81 4.63 4.99 4.78 4.70 4.85 0.730
Ever use of HRT Yes No
n = 551 n = 408
Model 1 4.70 4.60 4.81 4.88 4.76 5.00 0.026
Model 2 4.74 4.65 4.84 4.83 4.72 4.94 0.238
Model 3 4.77 4.68 4.85 4.80 4.70 4.90 0.648
Ever use of OC Yes No
n = 595 n = 364
Model 1 4.81 4.71 4.91 4.73 4.59 4.86 0.370
Model 2 4.85 4.75 4.94 4.67 4.54 4.79 0.034
Model 3 4.86 4.77 4.94 4.66 4.54 4.78 0.014
Age at menopausea ,50 years $50 years
n = 333 n = 360
Model 1 4.83 4.70 4.96 4.85 4.72 4.98 0.814
Model 2 4.80 4.68 4.93 4.88 4.76 5.00 0.404
Model 3 4.82 4.70 4.94 4.86 4.75 4.98 0.593
Time since menopausea #16 years .16 years
n = 370 n = 323
Model 1 4.87 4.69 5.04 4.82 4.66 4.98 0.760
Model 2 4.87 4.72 5.02 4.81 4.65 4.97 0.645
Model 3 4.81 4.65 4.96 4.87 4.73 5.01 0.584
Hysterectomy Yes No
n = 341 n = 618
Model 1 4.83 4.70 4.96 4.75 4.66 4.85 0.326
Model 2 4.78 4.66 4.90 4.78 4.69 4.87 0.979
Model 3 4.78 4.67 4.89 4.78 4.70 4.86 0.992
Bilateral oophorectomy Yes No
n = 62 n = 897
Model 1 4.93 4.62 5.23 4.77 4.69 4.85 0.334
Model 2 4.85 4.57 5.14 4.78 4.70 4.85 0.600
Model 3 4.91 4.65 5.18 4.77 4.70 4.84 0.310
Hot flashes Yes No
n = 418 n = 541
Model 1 4.84 4.72 4.96 4.74 4.63 4.84 0.229
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association of hot flashes and symptoms during menopausal
transition with uric acid levels.
Strength and limitations
The cross-sectional design of the study represents a limitation,
implicating that cause and effect relationships cannot be discerned.
Furthermore, although we adjusted for a variety of important
confounding variables, residual confounding cannot entirely be
excluded. Since diet has an impact on uric acid levels it is a further
limitation of our study that we could not adjust for dietary habits
except for alcohol intake. Recall bias is another limitation.
However, retrospective assessment of reproductive variables like
age at menarche [30] and age at menopause [31] has been shown
to be reliable and valid. Some reproductive factors in this study
were defined fairly broad, like ever use of oral contraceptives or
ever use of hormone replacement therapy, without adjustment for
the timing or duration of the intake. Only asking for the presence
of hot flashes and not taking into consideration the amount,
severity and duration might as well lead to an underestimation of
an association with uric acid levels.
The strengths of the study are the large number of females
randomly drawn from the general population, and the availability
of data on lifestyle and multiple risk factors, which were measured
according to a standardized protocol.
Another limitation is the multiple testing situation. Since all our
explaining variables are reproductive parameters which are
somehow correlated with each other, simple correction of p-values
would have been too conservative. We are aware, however, that in
this situation our results can only be seen as explorative, showing a
tendency, which have to be reproduced in bigger studies.
Conclusion and Implication
Earlier age at menarche, postmenopausal status and a history of
oral contraceptive use in postmenopausal women was associated
with higher uric acid levels. Other reproductive factors, including
parity, current or ever use of hormone replacement therapy,
current use of oral contraceptives, hysterectomy, bilateral
oophorectomy, hot flashes or depressive mood in relation to
menopausal transition were not associated with uric acid levels.
Further studies, in particular prospective studies are needed to
investigate the influence of reproductive parameters on serum
levels of uric acid and finally on the manifestation of chronic
diseases.
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